STC2 and lung carcinoma: Upregulated STC2 was involved in drug resistance in HCC by increasing P-glycoprotein and B-cell lymphoma 2 protein expression levels [43], and it imparted resistance against EGFR tyrosine kinase inhibitors in lung cancer [89], resistance of cervical cancer cells to cisplatin [90], and induced oxaliplatin resistance in colorectal cancer cells [91].